2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1498

Patterns of Interstitial Lung Disease and Associated Mortality in Rheumatoid Arthritis
Abstract Number: 225

Patterns of Joint Involvement in Gout Flares
Abstract Number: 405

Patterns of Medication Use in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
Abstract Number: 3042

PD-1–Expressing T Cells in GCA Fail to Promote Immune Tolerance Functions
Abstract Number: 2038

Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
Abstract Number: 1969

Peer Approaches to Lupus Self-Management (PALS): A Novel Lupus Peer Mentorship Intervention
Abstract Number: 212

Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
Abstract Number: 1842

Pentraxin 3 Level Positively Correlated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients
Abstract Number: 1378

Pentraxin-3 Level Predicts Vasculitis and Mucocutaneous Involvement in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 103

People with Rheumatoid Arthritis Recruited from an Online Patient Community May Differ from Clinical Populations in Symptoms and Impacts
Abstract Number: 3148

Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation
Abstract Number: 1174

Perceived Stress and Reported Cognitive Symptoms Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1070

Performance and External Validation of the Damage Index in Antiphospholipid Syndrome in Primary and Secondary APS Patients
Abstract Number: 1292

Performance of 18fluoride Sodium Positron Emission Tomography with Computed Tomography to Assess Inflammatory and Structural Sacroiliitis Respectively on Magnetic Resonance Imaging and Computed Tomography in Axial Spondyloarthritis
Abstract Number: 703

Performance of a New Spinal Mobility Index for Patients with Axial Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].